Artelo Biosciences Inc (ARTL) - Total Liabilities
Based on the latest financial reports, Artelo Biosciences Inc (ARTL) has total liabilities worth $4.07 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Artelo Biosciences Inc (ARTL) equity growth momentum to track the company's year-over-year net asset growth rate.
Artelo Biosciences Inc - Total Liabilities Trend (2014–2025)
This chart illustrates how Artelo Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data.
Artelo Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Artelo Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Trufin PLC
LSE:TRU
|
UK | GBX14.17 Million |
|
Oncternal Therapeutics Inc
NASDAQ:ONCT
|
USA | $6.45 Million |
|
Surya Oil & Gas Corp.
NASDAQ:SURY
|
USA | $2.00 Million |
|
Tijaria Polypipes Limited
NSE:TIJARIA
|
India | Rs823.57 Million |
|
Goobit Group AB
ST:BTCX
|
Sweden | Skr16.81 Million |
|
Golden Cross Resources Ltd
AU:GCR
|
Australia | AU$10.33 Million |
|
Castings PLC
LSE:CGS
|
UK | GBX40.76 Million |
|
Hynion AS
OL:HYN
|
Norway | Nkr29.09 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Artelo Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ARTL stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Artelo Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Artelo Biosciences Inc (2014–2025)
The table below shows the annual total liabilities of Artelo Biosciences Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.07 Million | +121.24% |
| 2024-12-31 | $1.84 Million | +42.60% |
| 2023-12-31 | $1.29 Million | +26.44% |
| 2022-12-31 | $1.02 Million | +72.18% |
| 2021-12-31 | $593.00K | +18.09% |
| 2020-12-31 | $502.18K | -50.84% |
| 2019-12-31 | $1.02 Million | +92.02% |
| 2018-12-31 | $531.97K | +1707.09% |
| 2017-12-31 | $29.44K | +69.28% |
| 2016-12-31 | $17.39K | +900.00% |
| 2015-12-31 | $1.74K | -111.81% |
| 2014-12-31 | $-14.73K | -- |
About Artelo Biosciences Inc
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a coc… Read more